title: A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone.
abstract: OBJECTIVE
  To compare live birth rates after fresh embryo transfer (ET) and cumulative ongoing pregnancy rates after fresh ET and frozen-thawed (ET) between continents and overall after one treatment cycle with corifollitropin alfa or recombinant FSH.
  
  
  METHODS
  Double-blind, multicenter, randomized controlled trial.
  
  
  METHODS
  Fourteen centers in North America (NA); 20 in Europe (EU).
  
  
  METHODS
  804 NA patients and 702 EU patients.
  
  
  METHODS
  Patients >60 kg received a single dose of corifollitropin alfa or daily rFSH for the first 7 days of controlled ovarian stimulation.
  
  
  METHODS
  Live birth rates.
  
  
  RESULTS
  Within each continent no differences were noted between the two treatment groups; however, between continents, the cumulative ongoing pregnancy rate and live birth rate were considerably higher in NA than in EU. The live birth rate in NA was 39.2% in both treatment groups compared with 31.5% and 28.8% in EU after corifollitropin alfa and rFSH treatment, respectively. Considering the number of embryos transferred, the live birth rate per ET was still higher in NA than in EU (42.7% v.s 36.8% with corifollitropin alfa and 41.6% vs. 30.9% with rFSH). Overall live birth rates after fresh ET were 35.6% and 34.4% (estimated difference 1.1% [95% confidence interval -3.7-5.8]), and the estimated cumulative live birth rates were 43.4% and 41.3% with corifollitropin alfa and rFSH, respectively.
  
  
  CONCLUSIONS
  Live birth rates and cumulative pregnancy rates were higher in NA than in EU after treatment with either corifollitropin alfa or daily rFSH; both treatment protocols provided equal success rates. CLINICALTRIALS.GOV IDENTIFIERS: NCT00703014 and NCT00702273.
authors.affiliation: Huntington Reproductive Center, Encino, California 91436, USA. boostanfarivf@havingbabies.com
authors.forename: Robert
authors.initials: R
authors.lastname: Boostanfar
authors.forename: Bernadette
authors.initials: B
authors.lastname: Mannaerts
authors.forename: Samuel
authors.initials: S
authors.lastname: Pang
authors.forename: Manuel
authors.initials: M
authors.lastname: Fernandez-Sanchez
authors.forename: Han
authors.initials: H
authors.lastname: Witjes
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
mesh_terms: D000293:Adolescent; D000328:Adult; D015925:Cryopreservation; D004624:Embryo Transfer; D005060:Europe; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage*; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage*; D006801:Humans; D009656:North America; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D043373:Follicle Stimulating Hormone, Human; D011994:Recombinant Proteins; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide; D005640:Follicle Stimulating Hormone